Compositions and methods for treating poxvirus infection
The present invention provides methods of treating a poxvirus infection, e.g., a vaccinia virus or a variola virus infection; and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from a poxviral infection. The present invention further provides methods of reducing the risk that an individual will develop a pathological poxvirus infection, such as a vaccinia virus infection or a variola virus infection, that has clinical sequelae. The methods generally involve administering a therapeutically effective amount of a Type I or Type III interferon receptor agonist and/or a Type II interferon receptor agonist for the treatment of a pox viral infection.
1 . A method of treating a poxvirus infection, the method comprising administering to an individual an effective amount of IFN-α.
2 . The method of claim 1 , wherein the IFN-α is administered concurrently with a vaccinia virus vaccine.
3 . The method of claim 1 , wherein the individual has been vaccinated with vaccinia virus.
4 . The method of claim 3 , wherein the IFN-α is administered from 1 to 30 days after vaccination.
5 . The method of claim 1 , wherein IFN-α is administered from 1 day to 1 year before administration of a vaccinia virus vaccine.
6 . The method of claim 1 , further comprising administering a vaccinia virus vaccine.
7 . The method of claim 1 , wherein the individual has been exposed to smallpox virus, and the IFN-α is administered within 24 hours of exposure to smallpox virus.
8 . The method of claim 1 , wherein the individual has been exposed to smallpox virus, and the IFN-α is administered within 48 hours of exposure to smallpox virus.
9 . The method of claim 1 , wherein the individual has been exposed to smallpox virus, and the IFN-α is administered 72 hours to 35 days after exposure to smallpox virus.
10 . A method of treating a poxvirus infection, the method comprising administering to an individual an effective amount of IFN-γ.
11 . The method of claim 10 , wherein the IFN-γ is administered concurrently with a vaccinia virus vaccine.
12 . The method of claim 10 , wherein the individual has been vaccinated with vaccinia virus.
13 . The method of claim 12 , wherein the IFN-γ is administered from 1 to 30 days after vaccination.
14 . The method of claim 10 , wherein IFN-γ is administered from 1 day to 1 year before administration of a vaccinia virus vaccine.
15 . The method of claim 10 , further comprising administering a vaccinia virus vaccine.
16 . The method of claim 10 , wherein the individual has been exposed to smallpox virus, and the IFN-γ is administered within 24 hours of exposure to smallpox virus.
17 . The method of claim 10 , wherein the individual has been exposed to smallpox virus, and the IFN-γ is administered within 48 hours of exposure to smallpox virus.
18 . The method of claim 10 , wherein the individual has been exposed to smallpox virus, and the IFN-γ is administered 72 hours to 35 days after exposure to smallpox virus.
19 . A method of treating a poxvirus infection, the method comprising administering to an individual effective amounts of IFN-γ and IFN-α.
20 . The method of claim 19 , wherein the IFN-γ and IFN-α are administered concurrently with a vaccinia virus vaccine.
21 . The method of claim 19 , wherein the individual has been vaccinated with vaccinia virus.
22 . The method of claim 21 , wherein the IFN-γ and IFN-α are administered from 1 to 30 days after vaccination.
23 . The method of claim 19 , wherein the IFN-γ and IFN-α are administered from 1 day to 1 year before administration of a vaccinia virus vaccine.
24 . The method of claim 19 , further comprising administering a vaccinia virus vaccine.
25 . The method of claim 19 , wherein the individual has been exposed to smallpox virus, and the IFN-γ and IFN-α are administered within 24 hours of exposure to smallpox virus.
26 . The method of claim 19 , wherein the individual has been exposed to smallpox virus, and the IFN-γ and IFN-α are administered within 48 hours of exposure to smallpox virus.
27 . The method of claim 19 , wherein the individual has been exposed to smallpox virus, and the IFN-γ and IFN-α are administered 72 hours to 35 days after exposure to smallpox virus.
28 . The method of claim 1 , further comprising administering an effective amount of a nucleotide analog or a nucleoside analog.
29 . The method of claim 1 , wherein the IFN-α is a consensus interferon.
30 . The method of claim 19 , wherein the IFN-α is a consensus interferon.
31 . The method of claim 10 , further comprising administering an effective amount of a nucleotide analog or a nucleoside analog.
32 . The method of claim 19 , further comprising administering an effective amount of a nucleotide analog or a nucleoside analog.